

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Check this box to indicate that a
transaction was made pursuant to a
contract, instruction or written plan for
the purchase or sale of equity securities
of the issuer that is intended to satisfy
the affirmative defense conditions of
Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Lin Xichen</u> (Last) (First) (Middle) <u>C/O STRUCTURE THERAPEUTICS INC.</u> <u>601 GATEWAY BLVD., SUITE 900</u> (Street) <u>SOUTH SAN FRANCISCO</u> <u>CA</u> <u>94080</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Structure Therapeutics Inc.</u> [<u>GPCR</u>] Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) <u>08/04/2026</u> 4. If Amendment, Date of Original Filed (Month/Day/Year)	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner ☒ Officer (give title below) Other (specify below) <u>CHIEF SCIENTIFIC OFFICER</u> 6. Individual or Joint/Group Filing (Check Applicable Line) ☒ Form filed by One Reporting Person Form filed by More than One Reporting Person
--	--	--

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Ordinary Shares	08/04/2026		M		11,817	A	\$0.34 ⁽¹⁾	240,777	D	
Ordinary Shares	08/04/2026		C		11,817 ⁽²⁾	D	\$0	228,960	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Share Option (right to buy)	\$0.34 ⁽¹⁾	08/04/2026		M			11,817	(3)	09/10/2029	Ordinary Shares	11,817	\$0	154,715 ⁽⁴⁾	D	
American Depositary Shares	(5)	08/04/2026		C		3,939 ⁽⁶⁾		(5)	(5)	Ordinary Shares	11,817	\$0	3,939	D	
American Depositary Shares	(5)	08/04/2026		S ⁽⁷⁾			3,100	(5)	(5)	Ordinary Shares	9,300	\$49.2857 ⁽⁸⁾⁽⁹⁾	839	D	
American Depositary Shares	(5)	08/04/2026		S ⁽⁷⁾			839	(5)	(5)	Ordinary Shares	2,517	\$50.029 ⁽⁸⁾⁽¹⁰⁾	0	D	

Explanation of Responses:

1. Reflects price per share in Ordinary Shares.
2. The Ordinary Shares were converted into American Depositary Shares as reported in Table II.
3. 1/4 of the Ordinary Shares vested one year after July 22, 2019 (the "Vesting Commencement Date"); the balance of the Ordinary Shares vested in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.
4. This reflects the number of Ordinary Shares remaining under the share option following the partial exercise of the share option for 11,817 Ordinary Shares.
5. Each American Depositary Share is convertible at any time, at the holder's election, into three Ordinary Shares of the Issuer. The American Depositary Shares have no expiration date.
6. 11,817 Ordinary Shares, which were acquired upon exercise of a share option, were converted into 3,939 American Depositary Shares.
7. The American Depositary Shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 26, 2026.
8. Reflects price per share in American Depositary Shares.
9. The weighted average sale price for the transaction reported was \$49.2857 and the range of prices were between \$48.66 and \$49.65. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.
10. The weighted average sale price for the transaction reported was \$50.0290, and the range of prices were between \$49.69 and \$50.33. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of American Depositary Shares sold at each price will be provided.

/s/ Jun Yoon, Attorney-in-Fact 08/05/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.